Repurposing of Drugs as Novel Influenza Inhibitors From Clinical Gene Expression Infection Signatures.

ABSTRACT: Influenza virus infections remain a major and recurrent public health burden. The intrinsic ever-evolving nature of this virus, the suboptimal efficacy of current influenza inactivated vaccines, as well as the emergence of resistance against a limited antiviral arsenal, highlight the critical need for novel therapeutic approaches. In this context, the aim of this study was to develop and validate an innovative strategy for drug repurposing as host-targeted inhibitors of influenza viruses and the rapid evaluation of the most promising candidates in Phase II clinical trials. We exploited in vivo global transcriptomic signatures of infection directly obtained from a patient cohort to determine a shortlist of already marketed drugs with newly identified, host-targeted inhibitory propert

SUBMITTER: Pizzorno A 

PROVIDER: S-EPMC6361841 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature